Next-generation compounds The GLP-1 landscape is not static
Now that telehealth companies can no longer sell the cheaper compounded medication, its unclear whether or not hell be able to afford to stay on a GLP-1
At present, several oral antidiabetic medications are used for the treatment of T2DM including, -glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists (GLP-1RAs), peroxisome proliferator-activated receptor (PPAR-) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodiumglucose transporter 2 (SGLT2) inhibitors
Retatrutide has a half-life of approximately six days, which supports once-weekly dosing
Studies suggest weight loss from the Wegovy pill is similar to that experienced with the brand's injectable form